Urol. praxi. 2016;17(3):143-144

LUTS u mu¾ù: komu nabídnout antimuskarinikum v kombinaci s alfablokátorem?

Published: August 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
LUTS u mu¾ù: komu nabídnout antimuskarinikum v kombinaci s alfablokátorem? Urol. praxi. 2016;17(3):143-144.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rees J, Bultitude M, Challacombe B. The management of lower urinary tract symptoms in men. BMJ. 2014; 348: g3861. Go to original source... Go to PubMed...
    2. Hanu¹ T, Zámeèník L, Dole¾al T, Karmazínová Z. Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic. Urol Int. 2011; 86(4): 407-413. Go to original source... Go to PubMed...
    3. Peters TJ, Donovan JL, Kay HE, et al. The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms. J Urol. 1997; 157(3): 885-889. Go to original source... Go to PubMed...
    4. Häkkinen JT, Hakama M, Huhtala H, et al. Impact of LUTS using bother index in DAN-PSS-1 questionnaire. Eur Urol. 2007; 51(2): 473-477; discussion 477-478. Go to original source... Go to PubMed...
    5. van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013; 64(6): 1003-1012. Go to original source... Go to PubMed...
    6. Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015; 67(2): 262-270. Go to original source... Go to PubMed...
    7. Chapple CR, Khullar V, Gabriel Z, et al.The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008; 54(3): 543-562. Go to original source... Go to PubMed...
    8. Gravas S, et al. EAU guidelines on the treatment of non-neurogenic male LUTS. 2016. http://uroweb.org/
    9. Abrams P, Avery K, Gardener N, et al. The International Consultation on Incontinence Modular Questionnaire: www.iciq.net. J Urol. 2006; 175(3 Pt 1): 1063-1066; discussion 1066. Go to original source... Go to PubMed...
    10. Kaplan SA, McCammon K, Fincher R, et al. Safety and tolerability of solifenacin add-on therapy to alphablocker treated men with residual urgency and frequency. J Urol 2009; 182(6): 2825-30. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.